Search research articles
Contact Us
Filters
Showing results (411-420 of 453) with videos related to
Page
of 46
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
August 18, 2012
Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung
Tobias J Grob, Ivonne Kannengiesser, Maria C Tsourlakis, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 23, 2015
Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest
Malte Kriegs, Kristin Gurtner, Yildiz Can, et al.
Journal of Veterinary Internal Medicine
|
December 30, 2022
Carbohydrate pellets to assess insulin dysregulation in horses
Melody A de Laat, Tobias Warnken, Julien Delarocque, et al.
The New England Journal of Medicine
|
April 27, 2022
CTLA-4 Blockade Resistance after Relatlimab and Nivolumab
Alexander M Menzies, Ines Pires da Silva, Claudia Trojaniello, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 25, 2021
Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition
J J Grob, A Guminski, J Malvehy, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 23, 2021
Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas
J J Grob, C Gaudy-Marqueste, A Guminski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2022
Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285]
B G M Hughes, E Munoz-Couselo, L Mortier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 22, 2021
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
B G M Hughes, E Munoz-Couselo, L Mortier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2014
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine
J-J Grob, M M Amonkar, S Martin-Algarra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
M R Middleton, J J Grob, N Aaronson, et al.
Page
of 46
Search research articles
Search
Showing results (411-420 of 453) with videos related to
Sort By:
Page
of 46
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
August 18, 2012
Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung
Tobias J Grob, Ivonne Kannengiesser, Maria C Tsourlakis, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 23, 2015
Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest
Malte Kriegs, Kristin Gurtner, Yildiz Can, et al.
Journal of Veterinary Internal Medicine
|
December 30, 2022
Carbohydrate pellets to assess insulin dysregulation in horses
Melody A de Laat, Tobias Warnken, Julien Delarocque, et al.
The New England Journal of Medicine
|
April 27, 2022
CTLA-4 Blockade Resistance after Relatlimab and Nivolumab
Alexander M Menzies, Ines Pires da Silva, Claudia Trojaniello, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 25, 2021
Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition
J J Grob, A Guminski, J Malvehy, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 23, 2021
Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas
J J Grob, C Gaudy-Marqueste, A Guminski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2022
Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285]
B G M Hughes, E Munoz-Couselo, L Mortier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 22, 2021
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
B G M Hughes, E Munoz-Couselo, L Mortier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2014
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine
J-J Grob, M M Amonkar, S Martin-Algarra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
M R Middleton, J J Grob, N Aaronson, et al.
Page
of 46